Johann-Matthias Graf von der Schulenburg

Johann-Matthias Graf von der Schulenburg

Auto-generated profile, based on publicly available information

Johann-Matthias Graf von der Schulenburg

Leibniz University Hannover, Center for Health Economics Research Hannover (CHERH), Hannover, Germany

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2018 in The European Journal of Health Economics
Verified
Journal Article
Open access
PDF file
BJBengt Jönsson
Bengt Jönsson
GHGrace Hampson
Grace Hampson
JMJonathan Michaels
Jonathan Michaels
ATAdrian Towse
Adrian Towse
JSJ.-Matthias Graf von der Schulenburg
J.-Matthias Graf von der Schulenburg
OWOlivier Wong
Olivier Wong
Background Advanced therapy medicinal products (ATMPs) are beginning to reach European markets, and questions are being asked about their value for patients and how healthcare systems should pay for them. Objectives To identify and discuss potential challenges of ATMPs in view of current health technology assessment (HTA) methodology—specifically economic evaluation methods—in Europe as it relates to ATMPs, and to suggest potential solutions to these challenges. Methods An Expert Panel reviewed current HTA principles and practices in relation to the specific characteristics of ATMPs. Results Three key topics were identified and prioritised for discussion—uncertainty, discounting, and health outcomes and value. The panel discussed that evidence challenges linked to increased uncertainty may be mitigated by collection of follow-on data, use of value of information analysis, and/or outcomes-based contracts. For discount rates, an international, multi-disciplinary forum should be established to consider the economic, social and ethical implications of the choice of rate. Finally, consideration of the feasibility of assessing the value of ATMPs beyond health gain may also be key for decision-making. Conclusions ATMPs face a challenge in demonstrating their value within current HTA frameworks. Consideration of current HTA principles and practices with regards to the specific characteristics of ATMPs and continued dialogue will be key to ensuring appropriate market access. Classification code I.

18 January 2017 in Journal of Medical Internet Research
Verified
Journal Article
Open access
FPFrédéric Pauer
Frédéric Pauer
SLSvenja Litzkendorf
Svenja Litzkendorf
JGJens Göbel
Jens Göbel
HSHolger Storf
Holger Storf
JZJan Zeidler
Jan Zeidler
JSJohann-Matthias Graf von der Schulenburg
Johann-Matthias Graf von der Schulenburg
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

25 August 2016 in Interactive Journal of Medical Research
Verified
Journal Article
Open access
FPFrédéric Pauer
Frédéric Pauer
JGJens Göbel
Jens Göbel
HSHolger Storf
Holger Storf
SLSvenja Litzkendorf
Svenja Litzkendorf
ABAna Babac
Ana Babac
THTobias Hartz
Tobias Hartz
Interactive Journal of Medical Research

20 November 2017 in Interactive Journal of Medical Research
Verified
Journal Article
Open access
ABAna Babac
Ana Babac
SLSvenja Litzkendorf
Svenja Litzkendorf
KSKatharina Schmidt
Katharina Schmidt
FPFrédéric Pauer
Frédéric Pauer
KDKathrin Damm
Kathrin Damm
JSJohann-Matthias Graf von der Schulenburg
Johann-Matthias Graf von der Schulenburg
Interactive Journal of Medical Research

1 June 2014 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
LGL. Goldbeck
L. Goldbeck
AFA. Fidika
A. Fidika
ARA. Reimann
A. Reimann
HHH. Hebestreit
H. Hebestreit
HHH.-E. Heuer
H.-E. Heuer
JSJ.-M. von der Schulenburg
J.-M. von der Schulenburg

11 May 2018 in JMIR Research Protocols
Verified
Journal Article
Open access
SLSvenja Litzkendorf
Svenja Litzkendorf
THTobias Hartz
Tobias Hartz
JGJens Göbel
Jens Göbel
HSHolger Storf
Holger Storf
FPFrédéric Pauer
Frédéric Pauer
MFMartin Frank
Martin Frank
Background: Recently, public and political interest has focused on people living with rare diseases and their health concerns. Due to the large number of different types of rare diseases and the sizable number of patients, taking action to improve the life of those affected is gaining importance. In 2013, the federal government of Germany adopted a national action plan for rare diseases, including the call to establish a central information portal on rare diseases (Zentrales Informationsportal uber seltene Erkrankungen, ZIPSE). Objective: The objective of this study, therefore, was to conduct scientific research on how such a portal must be designed to meet the needs of patients, their families, and medical professionals, and to provide high-quality information for information seekers. Methods: We chose a 3-step procedure to develop a needs-based prototype of a central information portal. In the first step, we determined the information needs of patients with rare diseases, their relatives, and health care professionals by means of qualitative interviews and their content-analytical evaluation. On the basis of this, we developed the basic structure of the portal. In the second step, we identified quality criteria for websites on rare diseases to ensure that the information linked with ZIPSE meets the quality demands. Therefore, we gathered existing criteria catalogs and discussed them in an expert workshop. In the third step, we implemented and tested the developed prototypical information portal. Results: A portal page was configured and made accessible on the Web. The structure of ZIPSE was based on the findings from 108 qualitative interviews with patients, their relatives, and health care professionals, through which numerous information needs were identified. We placed particularly important areas of information, such as symptoms, therapy, research, and advisory services, on the start page. Moreover, we defined 13 quality criteria, referring to factors such as author information, creation date, and privacy, enabling links with high-quality information. Moreover, 19 users tested all the developed routines based on usability and comprehensibility. Subsequently, we improved the visual presentation of search results and other important search functions. Conclusions: The implemented information portal, ZIPSE, provides high-quality information on rare diseases from a central point of access. By integrating the targeted groups as well as different experts on medical information during the construction, the website can assure an improved search for information for users. ZIPSE can also serve as a model for other Web-based information systems in the field of rare diseases.